I thought it was stated somewhere that they would be reported on at the AAIC meeting late next month. Not sure if it was in a PR or conference or on one of the seeking alpha blogs that report incorrect information at times. I don't have time to look at the moment but that was my understanding. I could be wrong
Finally had time to look Hanuman. This is from their June corporate slides.
• July 2021: announcement of clinical results on safety & cognition in patients who’ve completed at least 9 months of open-label treatment with simufilam. • New dataset will be presented July 29th at the 2021 Alzheimer’s Association International Conference (AAIC) in Denver. • AAIC’s scientific committee has invited the Company’s scientists to present the dataset as an oral presentation. • Sept 2021: announcement of clinical results on safety & cognition in patients who’ve completed at least 12 months of open-label treatment with simufilam.